This webinar offers an overview of the recent rescheduling of medical cannabis from a schedule I to schedule III substance. Attendees will learn about the difference between schedule I and schedule III substances, what the policy change means for people who use medical cannabis, the potential impact of rescheduling on cannabis retailers, and the potential for researchers to study cannabis with fewer DEA requirements. Attendees will also learn about the practical challenges and legal uncertainties that result from persistent tensions between federal and state laws and regulations.
Objectives:
- Differentiate between schedule I and schedule III substances.
- Examine how cannabis rescheduling impacts people who already use medical cannabis or plan to use medical cannabis.
- Describe what rescheduling means for businesses, increasing awareness of how dispensaries may change marketing campaigns or increase their reach to attract more consumers.
- Discuss looser regulations for cannabis research and the potential of developing cannabis-based medications in the future.
- Discuss legal and practical challenges that are likely to persist for researchers, businesses, medical professionals, patients and other actors.